pteroic acid
Recently Published Documents


TOTAL DOCUMENTS

53
(FIVE YEARS 0)

H-INDEX

14
(FIVE YEARS 0)

2005 ◽  
Vol 49 (9) ◽  
pp. 3652-3657 ◽  
Author(s):  
Eunice Nduati ◽  
Sonya Hunt ◽  
Eddy M. Kamau ◽  
Alexis Nzila

ABSTRACT We have tested the hypothesis that 2,4-diamino-6-hydroxymethyl-pteridine (DAP), 2,4-diaminopteroic acid (DAPA), and 2,4 diamino-N10-methyl-pteroic acid (DAMPA) could be converted into aminopterin (from DAP and DAPA) and methotrexate (from DAMPA), both of which are potent inhibitors of dihydrofolate reductase, a proven drug target for Plasmodium falciparum. DAP, DAPA, and DAMPA inhibited parasite growth in the micromolar range; DAMPA was the most active, with 50% inhibitory concentrations in vitro of 446 ng/ml against the antifolate-sensitive strain and 812 ng/ml against the highly resistant strain under physiological folate conditions. DAMPA potentiates the activity of the sulfone dapsone, an inhibitor of dihydropteroate synthase, but not that of chlorcycloguanil, a known inhibitor of dihydrofolate reductase (DHFR). Experiments with a Saccharomyces cerevisiae strain dependent upon the P. falciparum DHFR enzyme showed that DHFR is a target of DAMPA in that system. We hypothesize that DAMPA is converted to methotrexate by the parasite dihydrofolate synthase, which explains the synergy of DAMPA with dapsone but not with chlorcycloguanil. This de novo synthesis will not occur in the host, since it lacks the complete folate pathway. If this hypothesis holds true, the de novo synthesis of the toxic compounds could be used as a framework for the search for novel potent antimalarial antifolates.


2005 ◽  
Vol 127 (20) ◽  
pp. 7421-7426 ◽  
Author(s):  
Chun-Yen Ke ◽  
Carla J. Mathias ◽  
Mark A. Green
Keyword(s):  

2004 ◽  
Vol 14 (9) ◽  
pp. 2313-2317 ◽  
Author(s):  
Maciej Adamczyk ◽  
James R Fino ◽  
Phillip G Mattingly ◽  
Jeffrey A Moore ◽  
You Pan

1994 ◽  
Vol 3 (1-2) ◽  
pp. 91-100 ◽  
Author(s):  
J. A. Plumb ◽  
P. R. Liu ◽  
C. E. Butterworth

1986 ◽  
Vol 64 (7) ◽  
pp. 667-674 ◽  
Author(s):  
K. G. Scrimgeour

Folylpolyglutamate synthetase (FPGS) catalyzes the synthesis of the poly-γ-glutamate forms of tetrahydrofolate and its coenzyme adducts, as well as of the folate-analogue drugs. This paper reviews current knowledge of the preparations of FPGS from mammalian sources (rat, hog, mouse, and beef liver). Kinetic constants for the substrates and activators of FPGS are compared. Tetrahydrofolate and 5-formyltetrahydrofolate are excellent substrates for the enzyme. The Km values for the antifolates and their 7-hydroxy metabolites are much higher than those for the tetrahydrofolates. Aminopterin has higher activity with FPGS than does methotrexate, which partially explains its greater toxicity. 5-Formyltetrahydrofolate, which is used as a rescue agent in high-dose methotrexate-rescue chemotherapy, is a better alternate substrate of FPGS than is methotrexate and therefore is a potent competitive inhibitor of the glutamylation of methotrexate. Thus, low concentrations of the rescue agent prevent formation of cytotoxic polyglutamates of methotrexate. The pathway of the reaction is the addition of a glutamate residue to the terminal γ-carboxyl of the pteridine substrate. That longer folylpolyglutamates are poorer substrates possibly is a result of this addition pathway. Pteroic acid activates FPGS by lowering the Km value of the pteridine substrate. It also greatly increases the activity of the synthetase at physiological pH values.


Sign in / Sign up

Export Citation Format

Share Document